Generics Cos. Rip AstraZeneca's Crestor IP In Fed. Circ.
A slew of generic-drug companies defending against AstraZeneca PLC's multidistrict infringement litigation over Crestor told the Federal Circuit on Wednesday that a patent for the cholesterol drug is invalid because the...To view the full article, register now.
Already a subscriber? Click here to view full article